Cian Healthcare Ltd (CHCL.BO)
- Previous Close
3.1600 - Open
3.2200 - Bid 3.1300 x --
- Ask 3.2200 x --
- Day's Range
3.1200 - 3.2200 - 52 Week Range
2.9700 - 4.1400 - Volume
56,000 - Avg. Volume
65,473 - Market Cap (intraday)
77.987M - Beta (5Y Monthly) -0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-6.6100 - Earnings Date Feb 17, 2025 - Feb 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cian Healthcare Limited engages in the research, development, manufacture, marketing, and sale of pharmaceutical products in India. It offers pharmaceutical products in various therapeutic areas of orthopedics, gynecology, pediatrics, cardiac, diabetic, derma-cosmetic, pain management, antibiotics, central nervous system, neuro, critical care, gastro-intestinal, and vitamins and nutrient products. The company also provides male and female infertility, energy and immunity boosting, protein supplement, arthritis and joint pain, hepatoprotective, haematinic, and pet care products, as well as herbal supplement, cosmetics, and hospital products. It offers its products in the form of tablets, capsules, soft gels, liquid orals, ointments/creams, solid formulations, sachets, lozenges, and cosmetics. In addition, the company provides contract manufacturing services. It also exports its products to various countries, such as Afghanistan, Benin, Bhutan, Bolivia, Cambodia, Sri Lanka, and Myanmar. The company was incorporated in 2003 and is based in Pune, India.
cian.co257
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: CHCL.BO
View MorePerformance Overview: CHCL.BO
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHCL.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHCL.BO
View MoreValuation Measures
Market Cap
77.99M
Enterprise Value
605.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.17
Price/Book (mrq)
0.20
Enterprise Value/Revenue
1.26
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-34.29%
Return on Assets (ttm)
0.08%
Return on Equity (ttm)
-34.59%
Revenue (ttm)
481.76M
Net Income Avi to Common (ttm)
-165.19M
Diluted EPS (ttm)
-6.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
11.16M
Total Debt/Equity (mrq)
136.42%
Levered Free Cash Flow (ttm)
311.75M